Serum activin-A as a predictive and prognostic marker in critically ill patients with sepsis

Respirology

Volumn 21, Issue 5, 2016, Pages 891-897

  Lee, Jung Kyu ^a   Choi, Sun Mi ^b   Lee, Jinwoo ^b   Park, Young Sik ^b   Lee, Chang Hoon ^b   Yim, Jae Joon ^b   Yoo, Chul Gyu ^b   Kim, Young Whan ^b   Han, Sung Koo ^b   Lee, Sang Min ^b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

activin; acute phase proteins; biological markers; intensive care units; sepsis

Indexed keywords

ACTIVIN A; C REACTIVE PROTEIN; LACTIC ACID;

ADULT; APACHE; ARTICLE; CHARLSON COMORBIDITY INDEX; CRITICALLY ILL PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE;

EID: 84975048570     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12751     Document Type: Article

References (33)

1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273: 117–23.
2. Angus DC, van der Poll T. Severe sepsis and septic shock. N. Engl. J. Med. 2013; 369: 840–51.
3. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R et al. Surviving sepsis campaign guidelines committee including the pediatric S. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39: 165–228.
4. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit. Care Med. 1985; 13: 818–29.
5. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286: 1754–8.
6. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. Intensive Care Med. 1996; 22:707–10.
7. Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, Morello F, Lupia E, Moiraghi C, Mengozzi G et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit. Care 2013; 17: R168.
8. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, Fumagalli R, Mauri T, Isgro S, Fanizza C et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit. Care 2014;18:R6.
9. Rey C, Los Arcos M, Concha A, Medina A, Prieto S, Martinez P, Prieto B. Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Med. 2007; 33: 477–84.
10. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect. Dis. 2007; 7: 210–7.
11. Albrich WC, Harbarth S. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. Intensive Care Med. 2015; 41: 1739–51.
12. Hedger MP, de Kretser DM. The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev. 2013; 24: 285–95.
13. Robson NC, Phillips DJ, McAlpine T, Shin A, Svobodova S, Toy T, Pillay V, Kirkpatrick N, Zanker D, Wilson K et al. Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. Blood 2008; 111: 2733–43.
14. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 2004; 29: 265–73.
15. Huang HM, Chiou HY, Chang JL. Activin A induces erythroid gene expressions and inhibits mitogenic cytokine-mediated K562 colony formation by activating p38 MAPK. J. Cell. Biochem. 2006; 98: 789–97.
16. Verhamme FM, Bracke KR, Amatngalim GD, Verleden GM, Van Pottelberge GR, Hiemstra PS, Joos GF, Brusselle GG. Role of activin-A in cigarette smoke-induced inflammation and COPD. Eur. Respir. J. 2014; 43: 1028–41.
17. Kariyawasam HH, Pegorier S, Barkans J, Xanthou G, Aizen M, Ying S, Kay AB, Lloyd CM, Robinson DS. Activin and transforming growth factor-beta signaling pathways are activated after allergen challenge in mild asthma. J. Allergy Clin. Immunol. 2009; 124: 454–62.
18. Apostolou E, Stavropoulos A, Sountoulidis A, Xirakia C, Giaglis S, Protopapadakis E, Ritis K, Mentzelopoulos S, Pasternack A, Foster M, et al. Activin-A overexpression in the murine lung causes pathology that simulates acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2012; 185: 382–91.
19. McNeilly AS. Diagnostic applications for inhibin and activins. Mol. Cell. Endocrinol. 2012; 359: 121–5.
20. Yndestad A, Larsen KO, Oie E, Ueland T, Smith C, Halvorsen B, Sjaastad I, Skjonsberg OH, Pedersen TM, Anfinsen OG et al. Elevated levels of activin A in clinical and experimental pulmonary hypertension. J. Appl. Physiol. (1985) 2009; 106: 1356–64.
21. Wang HJ, Wang BZ, Zhang PJ, Deng J, Zhao ZR, Zhang X, Xiao K, Feng D, Jia YH, Liu YN et al. Identification of four novel serum protein biomarkers in sepsis patients encoded by target genes of sepsis-related miRNAs. Clin. Sci. (Lond.) 2014; 126: 857–67.
22. Michel U, Ebert S, Phillips D, Nau R. Serum concentrations of activin and follistatin are elevated and run in parallel in patients with septicemia. Eur. J. Endocrinol. 2003; 148: 559–64.
23. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 2003; 31: 1250–6.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987; 40: 373–83.
25. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 388–416.
26. Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob. Resist Infect Control 2014; 3: 32.
27. Jones KL, Brauman JN, Groome NP, de Kretser DM, Phillips DJ. Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 2000; 141: 1905–8.
28. Jones KL, de Kretser DM, Clarke IJ, Scheerlinck JP, Phillips DJ. Characterisation of the rapid release of activin A following acute lipopolysaccharide challenge in the ewe. J. Endocrinol. 2004; 182: 69–80.
29. Phillips DJ, de Kretser DM, Hedger MP. Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 2009; 20: 153–64.
30. Sugama S, Takenouchi T, Kitani H, Fujita M, Hashimoto M. Activin as an anti-inflammatory cytokine produced by microglia. J. Neuroimmunol. 2007; 192: 31–9.
31. Hedger MP, Phillips DJ, de Kretser DM. Divergent cell-specific effects of activin-A on thymocyte proliferation stimulated by phytohemagglutinin, and interleukin 1beta or interleukin 6 in vitro. Cytokine 2000; 12: 595–602.
32. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 2009; 15: 496–7.
33. Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, Phillips DJ. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl. Acad. Sci. U. S. A. 2007; 104: 16239–44.